154 related articles for article (PubMed ID: 38064148)
1. Cabergoline treatment for surgery-naïve non-functioning pituitary macroadenomas.
Ayalon-Dangur I; Turjeman A; Hirsch D; Robenshtok E; Tsvetov G; Gorshtein A; Masri H; Shraga-Slutzky I; Manisterski Y; Akirov A; Shimon I
Pituitary; 2024 Feb; 27(1):52-60. PubMed ID: 38064148
[TBL] [Abstract][Full Text] [Related]
2. Natural history of nonfunctioning pituitary macroadenomas followed without intervention: A retrospective cohort study.
Ayalon-Dangur I; Robenshtok E; Duskin-Bitan H; Tsvetov G; Gorshtein A; Akirov A; Shimon I
Clin Endocrinol (Oxf); 2023 Apr; 98(4):559-566. PubMed ID: 36600448
[TBL] [Abstract][Full Text] [Related]
3. Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?
de Herder WW; Reijs AE; Feelders RA; van Aken MO; Krenning EP; Tanghe HL; van der Lely AJ; Kwekkeboom DJ
Eur J Endocrinol; 2006 Nov; 155(5):717-23. PubMed ID: 17062888
[TBL] [Abstract][Full Text] [Related]
4. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of cabergoline therapy in patients with non-functioning pituitary adenomas: A single center clinical experience.
Vargas-Ortega G; González-Virla B; Balcázar-Hernández L; Arreola-Rosales R; Benitez-Rodríguez FJ; López Félix B; Mercado M
Arch Endocrinol Metab; 2022 Sept 08; 66(4):506-511. PubMed ID: 35758837
[TBL] [Abstract][Full Text] [Related]
6. Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma.
Iglesias P; Biagetti B; Araujo-Castro M; Alcázar V; Guerrero-Pérez F; Rivero N; Casteràs A; Gómez CG; Izquierdo BG; Torres VV; Pascual-Corrales E; Pavón I; Villabona C; Cordido F; Díez JJ
J Neurooncol; 2022 Nov; 160(2):351-359. PubMed ID: 36355257
[TBL] [Abstract][Full Text] [Related]
7. Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma: A Single-Center, Open-Label, 2-Year Randomized Clinical Trial.
Batista RL; Musolino NRC; Cescato VAS; da Silva GO; Medeiros RSS; Herkenhoff CGB; Trarbach EB; Cunha-Neto MB
Am J Clin Oncol; 2019 Feb; 42(2):221-227. PubMed ID: 30540568
[TBL] [Abstract][Full Text] [Related]
8. Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma.
Greenman Y; Bronstein MD
Eur J Endocrinol; 2021 Aug; 185(4):D11-D20. PubMed ID: 34288884
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Treatment of Non-Functioning Pituitary Adenomas.
Vargas-Ortega G; Gonzalez-Virla B; Romero-Gameros CA
Arch Med Res; 2023 Dec; 54(8):102917. PubMed ID: 37996269
[TBL] [Abstract][Full Text] [Related]
11. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.
Andersen M; Bjerre P; Schrøder HD; Edal A; Høilund-Carlsen PF; Pedersen PH; Hagen C
Clin Endocrinol (Oxf); 2001 Jan; 54(1):23-30. PubMed ID: 11167922
[TBL] [Abstract][Full Text] [Related]
12. Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas.
Garcia EC; Naves LA; Silva AO; de Castro LF; Casulari LA; Azevedo MF
Pituitary; 2013 Jun; 16(2):189-94. PubMed ID: 22740242
[TBL] [Abstract][Full Text] [Related]
13. Resistant prolactinomas: a case series of 26 patients.
Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I
Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
[TBL] [Abstract][Full Text] [Related]
14. Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline.
Lohmann T; Trantakis C; Biesold M; Prothmann S; Guenzel S; Schober R; Paschke R
Pituitary; 2001 Aug; 4(3):173-8. PubMed ID: 12138990
[TBL] [Abstract][Full Text] [Related]
15. Treatment of non-functioning pituitary adenoma with cabergoline: a systematic review and meta-analysis.
Botelho MS; Franzini ÍA; Nunes-Nogueira VDS; Boguszewski CL
Pituitary; 2022 Dec; 25(6):810-818. PubMed ID: 35902444
[TBL] [Abstract][Full Text] [Related]
16. The Role of Dopamine Agonists in Pituitary Adenomas.
Giraldi EA; Ioachimescu AG
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):453-474. PubMed ID: 32741482
[TBL] [Abstract][Full Text] [Related]
17. Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists.
Greenman Y; Cooper O; Yaish I; Robenshtok E; Sagiv N; Jonas-Kimchi T; Yuan X; Gertych A; Shimon I; Ram Z; Melmed S; Stern N
Eur J Endocrinol; 2016 Jul; 175(1):63-72. PubMed ID: 27150495
[TBL] [Abstract][Full Text] [Related]
18. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
19. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.
Biller BM; Molitch ME; Vance ML; Cannistraro KB; Davis KR; Simons JA; Schoenfelder JR; Klibanski A
J Clin Endocrinol Metab; 1996 Jun; 81(6):2338-43. PubMed ID: 8964874
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of the effects of somatostatin analogue therapy in non-functioning pituitary adenomas in comparison to acromegaly.
Zawada NB; Kunert-Radek J; Pawlikowski M; Pisarek H; Radek M
Endokrynol Pol; 2016; 67(3):292-8. PubMed ID: 27345147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
